Category IP Policies

US Supreme Court Eyes Patent-Enforced Post-Sale Restrictions

Few were surprised when, earlier this month, the US Supreme Court agreed to hear the appeal in Impression Products, Inc. v. Lexmark International. The case presents two important patent law issues, and the lower court’s ruling on these issues conflicts with Supreme Court precedents, according to many experts.

Podcast: ITIF’s Atkinson On Trade, Innovation, China In Trump’s Washington

A major shift is underway in Washington that is expected to have ramifications for global trade, innovation, and intellectual property enforcement, as Donald Trump steps into the United States presidency. IP-Watch caught up with Rob Atkinson, president of the Information Technology & Innovation Foundation to get his view on what's to come. Among the predictions: the Washington Consensus on trade gets turned on its head, enforcement will rise including at multilateral level, the US will have many new ideas but iPhones will not be made in the US, and a much-needed "reset" of the US policy on China will bring greater mutual respect - if done right.

UN General Assembly Resolution: TRIPS Flexibilities, High-Level Panel On Medicines Access

The United Nations General Assembly this month is considering a resolution committing to elevate health issues to the highest levels of foreign policy. The resolution includes references and commitments related to dozens of existing instruments and tools aimed at improving health, including a full range of those on access to medicines, such as patent flexibilities under trade rules, and the recent report of the UN Secretary-General’s High-Level Panel on access to medicines and innovation.

Patents And Health Debate Brings Key WIPO Committee To Standstill

After a day spent in informal meetings to try to agree on what should be the future work of the World Intellectual Property Organization patent law committee, delegates had to admit defeat. The main point of contention, according to sources, was the request by developing countries that the committee work on the issue of patents and access to medicines, and address the recommendations of the United Nations Secretary-General’s High Level Panel on Access to Medicines. This request was met by blunt refusal by some developed countries as beyond the realm of the work of the committee.